About Us

Company Overview

AbGenomics Holding Ltd. is a platform for facilitating global positioning and resource integration, which allows AbGenomics to thrive worldwide. AbGenomics International completed a share swap with AbGenomics Holding Ltd. to become a fully owned subsidiary of AbGenomics Holding Ltd. on January 3, 2017. The AbGenomics group is comprised of AbGenomics International Inc., a clinical-stage biopharmaceutical company located in the San Francisco Bay Area, and AbGenomics Research and Administration Center, located in Neihu Technology Park, Taipei (Taiwan). AbGenomics specializes in the development of novel best-in-class therapeutics for inflammatory/autoimmune diseases and cancers.

Our lead candidate AbGn-168H/Neihulizumab has demonstrated the proof of clinical efficacy in Phase II clinical trials for T-cell mediated diseases such as psoriasis and psoriatic arthritis. This innovative drug candidate has the potential to bring game-changing benefits to the patients with many T-cell mediated diseases. There are currently two ongoing clinical studies with it. One is a phase II trial in patients with TNF inhibitor and/or Entyvio or JAK inhibitor Refractory ulcerative colitis. The other is a phase I study in patients who develop steroid-refractory acute GvHD after allogeneic hematopoietic cell transplantation (HCT).

AbGenomics also has a rich portfolio of preclinical biobetter/biosuperior antibody-drug conjugates (ADC's) with near-term plans for clinical development. Using our proprietary linker-payload platform, which aims to overcome major obstacles in the development of ADC's, AbGenomics’ ADC’s could offer superior anti-tumor activity and safety profiles in various cancers with unmet medical needs. As the dose-escalation part of AbGn-107 phase I study is going well, the company is commencing the dose expansion part to explore preliminary efficacy of AbGn-107 therapy in patients with chemo-refractory, locally advanced, recurrent, or metastatic gastric, biliary, pancreatic, or colorectal cancer. AbGenomics expects to enroll approximately 116 patients in the study at multiple clinical sites in both US and Taiwan.

Our Mission

AbGenomics is committed to the development of innovative treatments and prevention against inflammatory/autoimmune disease and cancer. Through the advancement of our technology platforms we aim to:

Solve unmet medical needs

Create better alternatives to existing therapies for patients

Provide patients with affordable and accessible medicine